Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.
Gemcitabine
Immune checkpoint inhibition
Immunotherapy
Ipilimumab
Pancreatic cancer
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
21
06
2019
accepted:
16
10
2019
pubmed:
20
11
2019
medline:
22
6
2021
entrez:
20
11
2019
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) remains resistant to chemotherapy and immunotherapy individually because of its desmoplastic stroma and immunosuppressive tumor microenvironment. Synergizing cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint blockade with chemotherapy could overcome these barriers. Here we present results of a phase Ib trial combining ipilimumab and gemcitabine in advanced PDAC. This was a single-institution study with a 3 + 3 dose-escalation design. The primary objective was to determine the maximum tolerated dose (MTD). Secondary objectives included determining the toxicity profile, objective response rate (ORR), median progression-free survival (PFS), and overall survival (OS). Twenty-one patients were enrolled, 13 during dose escalation and 8 at the MTD. The median age was 66 years, 62% were female, 95% had stage IV disease, and 67% had received at least one prior line of therapy. The primary objective to establish the MTD was achieved at doses of ipilimumab 3 mg/kg and gemcitabine 1,000 mg/m Gemcitabine and ipilimumab is a safe and tolerable regimen for PDAC with a similar response rate to gemcitabine alone. As in other immunotherapy trials, responses were relatively durable in this study. Gemcitabine and ipilimumab is a safe and feasible regimen for treating advanced pancreatic cancer. Although one patient in this study had a relatively durable response of nearly 20 months, adding ipilimumab to gemcitabine does not appear to be more effective than gemcitabine alone in advanced pancreatic cancer.
Sections du résumé
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) remains resistant to chemotherapy and immunotherapy individually because of its desmoplastic stroma and immunosuppressive tumor microenvironment. Synergizing cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint blockade with chemotherapy could overcome these barriers. Here we present results of a phase Ib trial combining ipilimumab and gemcitabine in advanced PDAC.
MATERIALS AND METHODS
This was a single-institution study with a 3 + 3 dose-escalation design. The primary objective was to determine the maximum tolerated dose (MTD). Secondary objectives included determining the toxicity profile, objective response rate (ORR), median progression-free survival (PFS), and overall survival (OS).
RESULTS
Twenty-one patients were enrolled, 13 during dose escalation and 8 at the MTD. The median age was 66 years, 62% were female, 95% had stage IV disease, and 67% had received at least one prior line of therapy. The primary objective to establish the MTD was achieved at doses of ipilimumab 3 mg/kg and gemcitabine 1,000 mg/m
CONCLUSION
Gemcitabine and ipilimumab is a safe and tolerable regimen for PDAC with a similar response rate to gemcitabine alone. As in other immunotherapy trials, responses were relatively durable in this study.
IMPLICATIONS FOR PRACTICE
Gemcitabine and ipilimumab is a safe and feasible regimen for treating advanced pancreatic cancer. Although one patient in this study had a relatively durable response of nearly 20 months, adding ipilimumab to gemcitabine does not appear to be more effective than gemcitabine alone in advanced pancreatic cancer.
Identifiants
pubmed: 31740568
pii: theoncologist.2019-0473
doi: 10.1634/theoncologist.2019-0473
pmc: PMC7216436
doi:
Substances chimiques
Ipilimumab
0
Deoxycytidine
0W860991D6
Gemcitabine
0
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e808-e815Informations de copyright
© AlphaMed Press 2019.
Références
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697
pubmed: 30635425
Oncoimmunology. 2015 Apr 1;4(7):e1016709
pubmed: 26140246
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Clin Oncol. 2008 Dec 20;26(36):5950-6
pubmed: 19018089
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Clin Cancer Res. 2018 Mar 15;24(6):1326-1336
pubmed: 29367431
J Natl Cancer Inst. 2017 Jan 28;109(6):
pubmed: 28131992
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Br J Cancer. 1996 Jan;73(1):101-5
pubmed: 8554969
Clin Dev Immunol. 2011;2011:267539
pubmed: 21922022
J Clin Oncol. 2017 Dec 1;35(34):3851-3858
pubmed: 28678668
Invest New Drugs. 1994;12(1):29-34
pubmed: 7960602
Nat Rev Immunol. 2008 Jan;8(1):59-73
pubmed: 18097448
J Immunother. 2013 Sep;36(7):382-9
pubmed: 23924790
Clin Cancer Res. 2019 Sep 15;25(18):5493-5502
pubmed: 31126960
Lancet Oncol. 2017 Jan;18(1):31-41
pubmed: 27932067
J Clin Oncol. 2011 Dec 1;29(34):4548-54
pubmed: 21969517
Adv Biol Regul. 2015 Sep;59:19-35
pubmed: 26166735
Lancet Oncol. 2012 Sep;13(9):879-86
pubmed: 22894884
J Surg Oncol. 2017 Jul;116(1):55-62
pubmed: 28628715
Ann Oncol. 2014 Sep;25(9):1750-5
pubmed: 24907635
Clin Cancer Res. 2018 Mar 15;24(6):1287-1295
pubmed: 29298798
J Clin Oncol. 2000 Feb;18(3):684-92
pubmed: 10653884
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
J Clin Oncol. 2019 May 1;37(13):1062-1069
pubmed: 30817250
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
Clin Transl Sci. 2016 Apr;9(2):89-104
pubmed: 26924066
Immunotherapy. 2016 Feb;8(2):117-25
pubmed: 26787078
Cancer Immunol Res. 2014 Jul;2(7):616-31
pubmed: 24942756
Br J Cancer. 2017 Jun 27;117(1):33-40
pubmed: 28588322
N Engl J Med. 2012 Mar 8;366(10):925-31
pubmed: 22397654
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
J Immunother. 2010 Oct;33(8):828-33
pubmed: 20842054
Clin Cancer Res. 2001 Mar;7(3 Suppl):925s-932s
pubmed: 11300493
Lancet Oncol. 2014 Jul;15(8):829-40
pubmed: 24954781
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140